Bliss GVS Pharma Ltd

₹ 121 -0.86%

21 May 2:07 p.m.

About

Incorporated in 1984, Bliss GVS Pharma Limited is engaged in manufacturing, marketing, trading and export of pharmaceutical formulations in the form of suppositories, pessaries, capsules, tablets, and syrups.

Key Points

Product Portfolio:
The company manufactures, markets, and exports over 150 branded formulations across 60+ therapeutic segments, including anti-malarial, anti-fungal, anti-bacterial, antibiotic, anti-inflammatory, contraceptive, and anti-diabetic. It sells these formulations as suppositories, pessaries, capsules, tablets, and syrups. Its portfolio includes over 150 brands such as P-Alaxin, Lonart, Funbact, and Lofnac. ^[1] ^[2]

Website BSE NSE

Market Cap ₹ 1,271 Cr.
Current Price ₹ 121
High / Low ₹ 186 / 92.2
Stock P/E 18.4
Book Value ₹ 100
Dividend Yield 0.41 %
ROCE 9.19 %
ROE 6.74 %
Face Value ₹ 1.00

Add ratio to table

Edit ratios

Pros

Company is almost debt free.

Cons

The company has delivered a poor sales growth of 8.59% over past five years.
Company has a low return on equity of 8.00% over last 3 years.
Earnings include an other income of Rs.36.2 Cr.
Dividend payout has been low at 8.02% of profits over last 3 years
Company has high debtors of 234 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations

Part of BSE Healthcare BSE SmallCap BSE Allcap

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
	138	147	139	169	143	109	171	161	164	149	183	180	156
	120	128	112	135	133	98	129	133	139	122	157	154	142
Operating Profit	19	19	27	33	11	11	42	29	25	27	25	26	14
OPM %	14%	13%	19%	20%	8%	10%	25%	18%	15%	18%	14%	14%	9%
	12	19	14	11	6	7	11	8	-33	7	8	12	9
Interest	2	2	2	1	5	1	1	2	2	1	3	1	1
Depreciation	3	4	4	4	4	5	6	6	6	6	6	7	7
Profit before tax	26	32	35	40	8	11	46	29	-15	26	24	30	14
Tax %	27%	23%	28%	27%	28%	31%	26%	27%	-25%	26%	29%	29%	20%
	19	25	25	29	6	8	34	21	-11	19	17	21	11
EPS in Rs	1.84	2.37	2.45	2.81	0.59	0.72	3.25	1.98	-1.09	1.85	1.62	2.00	1.09
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
	288	313	326	348	298	427	442	466	636	598	605	667
	222	227	230	247	209	331	342	374	527	508	498	576
Operating Profit	66	86	97	101	88	95	100	91	109	90	107	92
OPM %	23%	28%	30%	29%	30%	22%	23%	20%	17%	15%	18%	14%
	30	21	23	9	11	33	37	18	35	51	-8	36
Interest	9	11	14	9	7	3	7	4	4	10	6	7
Depreciation	4	5	6	6	6	6	9	14	14	15	24	27
Profit before tax	82	91	100	95	87	120	122	91	126	116	70	94
Tax %	34%	34%	35%	38%	34%	38%	24%	26%	27%	26%	28%	27%
	54	60	66	59	57	74	92	68	93	85	51	69
EPS in Rs	5.23	5.82	6.36	5.73	5.53	7.22	8.95	6.54	8.94	8.21	4.84	6.55
Dividend Payout %	10%	12%	8%	10%	18%	14%	6%	8%	6%	6%	10%	8%

Compounded Sales Growth
10 Years:	8%
5 Years:	9%
3 Years:	2%
TTM:	10%

Compounded Profit Growth
10 Years:	1%
5 Years:	-6%
3 Years:	-9%
TTM:	-9%

Stock Price CAGR
10 Years:	0%
5 Years:	6%
3 Years:	19%
1 Year:	12%

Return on Equity
10 Years:	11%
5 Years:	9%
3 Years:	8%
Last Year:	7%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	10	10	10	10	10	10	10	10	10	10	10	11
Reserves	305	358	422	481	531	593	673	745	841	927	978	1,048
	86	90	81	75	94	72	93	92	90	81	78	68
	85	97	71	99	59	61	79	98	139	122	87	93
Total Liabilities	486	555	585	666	694	736	855	946	1,080	1,140	1,153	1,220
	54	82	79	76	73	79	180	175	225	326	331	369
CWIP	4	0	2	2	0	43	0	2	22	3	8	21
Investments	19	19	21	21	18	18	18	18	18	18	19	19
	409	454	483	567	602	596	657	750	815	793	795	812
Total Assets	486	555	585	666	694	736	855	946	1,080	1,140	1,153	1,220

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
	65	15	60	38	23	48	63	67	114	44	126	97
	-24	-19	-15	-29	16	-68	-60	-62	-92	-13	-110	-78
	-3	-31	-35	-15	-22	9	-6	-12	-13	-26	-21	-27
Net Cash Flow	38	-35	10	-6	17	-11	-3	-6	9	5	-4	-7

Ratios

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Debtor Days	232	246	280	251	346	293	334	273	234	243	241	234
Inventory Days	53	58	59	61	100	89	93	121	96	86	109	86
Days Payable	147	130	94	139	88	50	86	96	89	88	66	64
Cash Conversion Cycle	138	173	245	173	357	332	342	298	241	241	283	257
Working Capital Days	163	216	263	400	553	367	401	367	294	323	313	278
ROCE %	25%	24%	23%	19%	15%	19%	18%	12%	14%	13%	11%	9%

Shareholding Pattern

Numbers in percentages

7 Recently

	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
	34.51%	34.55%	34.46%	35.04%	35.12%	35.06%	34.97%	34.97%	34.90%	34.82%	35.10%	35.29%
	17.17%	16.68%	16.53%	16.60%	16.50%	16.31%	15.35%	14.74%	13.24%	12.13%	13.51%	13.18%
	6.65%	6.64%	6.63%	6.63%	6.62%	6.61%	6.60%	6.59%	6.58%	6.56%	6.55%	6.55%
	41.67%	42.13%	42.35%	41.73%	41.73%	42.00%	43.08%	43.71%	45.27%	46.49%	44.84%	44.98%
No. of Shareholders	46,327	45,753	44,983	43,041	42,182	43,234	40,758	45,157	44,737	52,937	49,558	49,517

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
	60.16%	60.16%	41.60%	41.60%	33.31%	33.14%	35.04%	34.97%	35.29%
	5.44%	10.84%	23.87%	24.16%	22.83%	17.33%	16.60%	14.74%	13.18%
	0.25%	0.14%	1.62%	2.96%	6.72%	6.66%	6.63%	6.59%	6.55%
	34.15%	28.86%	32.91%	31.28%	37.14%	42.87%	41.73%	43.71%	44.98%
No. of Shareholders	15,811	19,930	15,010	14,151	28,543	45,866	43,041	45,157	49,517

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

All

Annual reports

Credit ratings

Concalls

Aug 2019

Transcript

Notes
PPT
May 2019

Transcript

Notes
PPT
Feb 2019

Transcript

Notes
PPT
Nov 2018

Transcript

Notes
PPT
Aug 2018

Transcript

Notes
PPT
May 2018

Transcript

Notes
PPT
Jan 2018

Transcript

Notes
PPT